Showing 1141-1150 of 1614 results for "".
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- Eyenovia: Positive Evidence that Optejet Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Dropshttps://modernod.com/news/eyenovia-positive-evidence-that-optejet-delivery-technology-decreased-inflammation-from-preserved-glaucoma-solutions-compared-to-drops/2481349/Eyenovia announced results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatm
- AcuFocus Announces First Commercial Patients Treated With the IC-8 Apthera IOLhttps://modernod.com/news/acufocus-announces-first-commercial-patients-treated-with-the-ic-8-apthera-iol/2481329/AcuFocus announced that Vance Thompson, MD, of Vance Thompson Vision, Sioux Falls, South Dakota has commercially implanted the first patients with the IC-8 Apthera IOL. The first and only small aperture, non-toric extended depth of focus IOL, the Apthera IOL is FDA approved fo
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- CORD Files for Premarket Approval with the FDA for the SC9 IOL for Cataract Surgeryhttps://modernod.com/news/cord-files-for-premarket-approval-with-the-fda-for-the-sc9-iol-for-cataract-surgery/2481284/Cumming Ophthalmic Research and Development (CORD) announced that it has submitted a premarket approval (PMA) application to the FDA for the Model SC9 IOL. The SC9 is the brainchild of Stuart Cumming, MD, FACS, FRCOphth, who has over one hundred patents related to IOLs. D
- ViaLase Makes Several Appointments to its Executive Teamhttps://modernod.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/ViaLase announced the appointments of Tom Frinzi as Executive Chairman of the Board; Richard Lewis, MD, as Chief Medical Officer; Shawn O'Neil as Chief Commercial Officer; and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives w
- LSU Health New Orleans Develops New Human Cell Line to Study Blinding Eye Disordershttps://modernod.com/news/lsu-health-new-orleans-develops-new-human-cell-line-to-study-blinding-eye-disorders/2481175/Under the direction of Boyd Professor Nicolas Bazan, MD, PhD, scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. Called ABC, these cells so closely resemble and retain the properties of n